Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Innate Pharma SA

< Previous 1 2 3 4 Next >
Innate Pharma Announces Its Participation to Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma 2024 Financial Calendar
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Abstracts Selected for ESMO Congress 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of October 3, 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Provides Update on Lacutamab Clinical Program
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Reports First Half 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Participate in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
First Patient Dosed in SAR’514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of July 1, 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights Proprietary Tetra-specific ANKET® NK Cell Engager IPH6501 at the EHA 2023 Congress
From Innate Pharma SA
Via Business Wire
Tickers IPHA
SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of June 1, 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR’579 / IPH6101 in R/R AML
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Outcome of Innate Pharma’s 2023 Annual General Meeting
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Reports First Quarter 2023 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of shares and voting rights of Innate Pharma as of May 1, 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Conference Call and Webcast for Q1 Business Update
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Establishes a New At-The-Market (“ATM”) Program on Nasdaq
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Participate in Upcoming Investor Conference
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Number of Shares and Voting Rights of Innate Pharma as of April 1, 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 12, 2023
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Files Its 2022 Universal Registration Document (Document d’enregistrement universel) and 2022 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
Tickers IPHA
Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program
From Innate Pharma SA
Via Business Wire
Tickers IPHA
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.